Screener
Ultragenyx Pharmaceutical RARE Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income | 5 | 6 | 11 | 13 |
| Non-cash interest expense on liabilities for sales of future royalties | (22) | (14) | (43) | (28) |
| Other income | 1 | 2 | 1 | 2 |
| Loss before income taxes | (91) | (114) | (275) | (264) |
| Provision for income taxes | (1) | (1) | (2) | (2) |
| Net loss | $(92) | $(115) | $(277) | $(266) |
| Net loss per share, basic and diluted | $(0.90) | $(1.17) | $(2.73) | $(2.73) |
| Shares used in computing net loss per share, basic and diluted | 101.9 | 98.5 | 101.3 | 97.4 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's income tax?
- Ultragenyx Pharmaceutical (RARE) reported income tax of $1M in Q2 2026.
- How has Ultragenyx Pharmaceutical's income tax changed year-over-year?
- Ultragenyx Pharmaceutical's income tax decreased by 0.0% year-over-year, from $1M to $1M.
- What is the long-term trend for Ultragenyx Pharmaceutical's income tax?
- Over 3 years (2021 to 2025), Ultragenyx Pharmaceutical's income tax has grown at a 53.1% compound annual growth rate (CAGR), from $1.04M to $3.74M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Ultragenyx Pharmaceutical's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude